Stockreport

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Palisade Bio, Inc.  (PALI) 
PDF – Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end [Read more]